The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer-Reference-Cited by-同舟云学术

The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer

Published:2019-08-29 Issue:12 Volume:45 Page:2435-2439
ISSN:1341-8076
Container-title:Journal of Obstetrics and Gynaecology Research
language:en
Short-container-title:J. Obstet. Gynaecol. Res.

Author:

Shimizu Yusuke¹²,Kajiyama Hiroaki²^ORCID,Yoshida Kosuke²^ORCID,Tamauchi Satoshi²^ORCID,Nakanishi Toru³,Kikkawa Fumitaka²^ORCID

Affiliation:

1. Department of Gynecologic OncologyAichi Cancer Center Hospital Nagoya Japan

2. Department of Obstetrics and GynecologyGraduate School of Medicine, Nagoya University Nagoya Japan

3. Department of Obstetrics and GynecologyTohoku Medical and Pharmaceutical University Sendai Japan

Publisher

Wiley

Subject

Obstetrics and Gynecology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jog.14112

Reference17 articles.

1. Pattern and prognostic factors in patients with malignant ascites: a retrospective study

2. Prognostic importance of ascites in ovarian carcinoma

3. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer

4. Vascular endothelial growth factor‐trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model;Byrne AT;Clin Cancer Res,2003

5. The Current and Future Management of Malignant Ascites

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels;Journal of Obstetrics and Gynaecology;2023-05-15

2. A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents;Frontiers in Pharmacology;2022-08-24

3. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition;Frontiers in Immunology;2021-04-14

4. Bevacizumab for malignant pleural effusion in ovarian clear cell carcinoma: a case report;European Journal of Gynaecological Oncology;2021

5. Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial;Translational Cancer Research;2020-04